Latest News- Infantile Spasms Therapeutics Market: Parenteral is expected to lead the Route Of Administration segment during 2025-2029

The Infantile Spasms Therapeutics Market is being driven by Advancements in research in neurology and epilepsy

The Infantile Spasms Therapeutics Market is expected to grow at a CAGR of 5% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 85.3 million. The global infantile spasms therapeutics market is undergoing significant growth, driven by the increasing exploration of gene therapy as an effective treatment method. Gene therapy, a promising approach, targets the genetic causes of infantile spasms directly. Researchers are actively investigating techniques to modify or replace faulty genes linked to the condition, aiming to regulate neural activity and alleviate spasms. A landmark development in 2024 was the approval of Vigafyde, a ready-to-use oral solution of vigabatrin, specifically for pediatric patients with infantile spasms. This approval marks a significant advancement, providing a more accessible formulation for children afflicted by this condition. 

Get more information on Infantile Spasms Therapeutics Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Route Of Administration
  • Parenteral
  • Oral
• Drug Class
  • Anticonvulsants
  • Corticosteroids
  • Others
• Distribution Channel
  • Offline
  • Online
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia
    • China
    • India
    • Japan
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Advancements in research in neurology and epilepsy
• Rising demand for infantile spasms therapeutics amid increasing prevalence
• Increasing awareness and emphasis on early diagnosis of infantile spasms

However, the market also witnesses some limitations, which are as follows:

• Lack of awareness about infantile spasms among healthcare professionals and caregivers
• Complexity and varied pathophysiology of infantile spasms
• High costs associated with research, clinical trials, and development

Benefits of Buying Global Infantile Spasms Therapeutics Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Infantile Spasms Therapeutics Market Research Report

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Infantile Spasms market focuses on the development of therapeutics for treating seizures in young children suffering from Infantile Spasms, a form of epilepsy syndrome. Seizures, characterized by body stiffening, arm and leg jerks, head bending forward, and back arching, typically occur in children between four months and one year of age. Causes include brain tumors, birth injuries, infection, and genetic changes. Steroids, hormone therapy, and corticotropin injection gel are current therapeutic options. Diagnostic tools include physical examination, neurological examination, MRI, blood, and urine examinations. Sustained results can be achieved through monotherapy or combination therapy with antiseizure medications.

Market Research Overview

The Infantile Spasms therapeutics market encompasses businesses involved in the research and development (R&D) or production of various treatments for this epilepsy syndrome affecting young children, typically between the ages of four months and one year. This market segment falls under the larger global pharmaceuticals industry, which is projected to experience significant growth due to several factors. One key driver is the increasing population aging, with estimates suggesting that by 2050, approximately one-quarter of the US population and European populations will be over 60 years old. This demographic shift will fuel demand for various healthcare products and services, including pharmaceuticals, as the elderly population tends to require more medications to manage chronic conditions. The Infantile Spasms therapeutics market is poised to benefit from this trend, as these treatments are crucial for managing the seizures associated with this condition.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/